| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clozapine | 45 | 2024 | 506 | 8.120 |
Why?
|
| Antipsychotic Agents | 81 | 2024 | 3061 | 7.530 |
Why?
|
| Schizophrenia | 107 | 2024 | 6915 | 5.880 |
Why?
|
| Schizophrenic Psychology | 37 | 2019 | 1646 | 2.300 |
Why?
|
| Catatonia | 5 | 2023 | 178 | 1.880 |
Why?
|
| Psychotic Disorders | 31 | 2024 | 3193 | 1.860 |
Why?
|
| Psychiatry | 14 | 2018 | 1689 | 1.610 |
Why?
|
| Neutropenia | 4 | 2021 | 884 | 1.360 |
Why?
|
| Mental Disorders | 15 | 2023 | 6796 | 1.330 |
Why?
|
| Referral and Consultation | 9 | 2024 | 3598 | 0.920 |
Why?
|
| Delayed-Action Preparations | 8 | 2023 | 961 | 0.920 |
Why?
|
| Stuttering | 1 | 2023 | 25 | 0.880 |
Why?
|
| Plague | 1 | 2023 | 20 | 0.870 |
Why?
|
| Electroconvulsive Therapy | 3 | 2024 | 502 | 0.860 |
Why?
|
| Physician's Role | 6 | 2016 | 918 | 0.830 |
Why?
|
| Risperidone | 9 | 2023 | 379 | 0.830 |
Why?
|
| Physician-Patient Relations | 9 | 2016 | 3242 | 0.790 |
Why?
|
| Psychophysiologic Disorders | 2 | 2016 | 221 | 0.790 |
Why?
|
| Somatoform Disorders | 2 | 2016 | 423 | 0.720 |
Why?
|
| Seizures, Febrile | 1 | 2021 | 108 | 0.720 |
Why?
|
| Antiviral Agents | 4 | 2016 | 3061 | 0.710 |
Why?
|
| Ileus | 1 | 2020 | 57 | 0.710 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3085 | 0.660 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 3205 | 0.660 |
Why?
|
| Schizophrenia, Paranoid | 4 | 2010 | 102 | 0.650 |
Why?
|
| Treatment Refusal | 3 | 2016 | 430 | 0.630 |
Why?
|
| Phencyclidine | 1 | 2018 | 60 | 0.630 |
Why?
|
| Sialorrhea | 4 | 2005 | 25 | 0.610 |
Why?
|
| Delirium | 4 | 2020 | 1663 | 0.580 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2017 | 32 | 0.580 |
Why?
|
| Tetrabenazine | 1 | 2017 | 18 | 0.580 |
Why?
|
| Psychosomatic Medicine | 2 | 2015 | 71 | 0.580 |
Why?
|
| Hepatitis C | 3 | 2016 | 1579 | 0.570 |
Why?
|
| Haloperidol | 4 | 2014 | 389 | 0.570 |
Why?
|
| Community Psychiatry | 2 | 2016 | 19 | 0.560 |
Why?
|
| Decision Making | 5 | 2014 | 3925 | 0.560 |
Why?
|
| Patient Compliance | 5 | 2016 | 2688 | 0.550 |
Why?
|
| Ribavirin | 2 | 2010 | 396 | 0.550 |
Why?
|
| Medication Adherence | 6 | 2022 | 2165 | 0.550 |
Why?
|
| Humans | 179 | 2024 | 760621 | 0.540 |
Why?
|
| Triazines | 1 | 2018 | 310 | 0.540 |
Why?
|
| Behavioral Symptoms | 2 | 2016 | 185 | 0.530 |
Why?
|
| Mental Competency | 2 | 2014 | 175 | 0.530 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 186 | 0.530 |
Why?
|
| Internship and Residency | 8 | 2018 | 5870 | 0.530 |
Why?
|
| Valine | 2 | 2017 | 409 | 0.530 |
Why?
|
| Uridine Monophosphate | 1 | 2016 | 68 | 0.520 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 766 | 0.500 |
Why?
|
| Psychophysiology | 1 | 2015 | 136 | 0.500 |
Why?
|
| Fluorenes | 1 | 2016 | 156 | 0.490 |
Why?
|
| Interferons | 2 | 2010 | 705 | 0.490 |
Why?
|
| Communicable Diseases | 2 | 2023 | 878 | 0.490 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 130 | 0.480 |
Why?
|
| Tobacco Use Disorder | 4 | 2019 | 700 | 0.480 |
Why?
|
| Legal Guardians | 2 | 2016 | 57 | 0.480 |
Why?
|
| Quinolones | 4 | 2012 | 377 | 0.480 |
Why?
|
| Self-Help Groups | 1 | 2016 | 189 | 0.480 |
Why?
|
| Dissent and Disputes | 2 | 2015 | 146 | 0.480 |
Why?
|
| Palmitates | 1 | 2014 | 70 | 0.470 |
Why?
|
| Benzimidazoles | 2 | 2017 | 858 | 0.470 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 844 | 0.460 |
Why?
|
| Secondary Prevention | 1 | 2021 | 1548 | 0.460 |
Why?
|
| Smoking Cessation | 9 | 2019 | 2064 | 0.450 |
Why?
|
| HIV Infections | 7 | 2016 | 17165 | 0.450 |
Why?
|
| Professional Role | 1 | 2016 | 310 | 0.440 |
Why?
|
| Benzodiazepines | 12 | 2018 | 1131 | 0.420 |
Why?
|
| Isoxazoles | 1 | 2014 | 230 | 0.420 |
Why?
|
| Vulnerable Populations | 3 | 2014 | 696 | 0.420 |
Why?
|
| Publications | 1 | 2015 | 194 | 0.420 |
Why?
|
| Biological Psychiatry | 2 | 2010 | 26 | 0.410 |
Why?
|
| Drug Monitoring | 3 | 2020 | 965 | 0.410 |
Why?
|
| Myocarditis | 2 | 2021 | 766 | 0.400 |
Why?
|
| Adult | 93 | 2024 | 219994 | 0.390 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2013 | 1988 | 0.390 |
Why?
|
| Social Responsibility | 2 | 2012 | 386 | 0.380 |
Why?
|
| Internet | 2 | 2016 | 3078 | 0.380 |
Why?
|
| Morgellons Disease | 1 | 2010 | 4 | 0.380 |
Why?
|
| AIDS Dementia Complex | 1 | 2012 | 153 | 0.370 |
Why?
|
| Citalopram | 4 | 2023 | 402 | 0.370 |
Why?
|
| Gender Identity | 1 | 2016 | 698 | 0.370 |
Why?
|
| Neurosciences | 1 | 2015 | 353 | 0.370 |
Why?
|
| Piperazines | 6 | 2012 | 2525 | 0.370 |
Why?
|
| Patient Discharge | 2 | 2014 | 3476 | 0.360 |
Why?
|
| Inservice Training | 1 | 2012 | 375 | 0.350 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2019 | 489 | 0.350 |
Why?
|
| Models, Educational | 1 | 2012 | 373 | 0.340 |
Why?
|
| Prolactinoma | 1 | 2010 | 113 | 0.340 |
Why?
|
| Central Nervous System Stimulants | 3 | 2009 | 1174 | 0.340 |
Why?
|
| Lithium Carbonate | 1 | 2010 | 179 | 0.340 |
Why?
|
| Male | 100 | 2024 | 359744 | 0.340 |
Why?
|
| Polypharmacy | 1 | 2012 | 307 | 0.330 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2010 | 99 | 0.330 |
Why?
|
| Pandemics | 5 | 2023 | 8624 | 0.320 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 5325 | 0.320 |
Why?
|
| Duodenum | 1 | 2012 | 486 | 0.320 |
Why?
|
| Psychiatric Status Rating Scales | 20 | 2019 | 6015 | 0.310 |
Why?
|
| Fatigue | 3 | 2010 | 1544 | 0.310 |
Why?
|
| Health Literacy | 1 | 2013 | 440 | 0.310 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 662 | 0.310 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 1031 | 0.300 |
Why?
|
| Cooperative Behavior | 5 | 2016 | 1500 | 0.290 |
Why?
|
| Middle Aged | 70 | 2024 | 220352 | 0.290 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 894 | 0.290 |
Why?
|
| Drug Therapy, Combination | 17 | 2019 | 6498 | 0.290 |
Why?
|
| Epilepsy | 1 | 2022 | 3267 | 0.290 |
Why?
|
| Models, Psychological | 3 | 2010 | 827 | 0.280 |
Why?
|
| Female | 94 | 2024 | 391270 | 0.280 |
Why?
|
| Diagnosis, Differential | 15 | 2019 | 12965 | 0.270 |
Why?
|
| Patient Preference | 1 | 2014 | 922 | 0.270 |
Why?
|
| Double-Blind Method | 27 | 2019 | 12427 | 0.270 |
Why?
|
| Ambulatory Care Facilities | 2 | 2012 | 926 | 0.270 |
Why?
|
| Metabolic Diseases | 5 | 2013 | 686 | 0.270 |
Why?
|
| Cognition Disorders | 10 | 2014 | 3976 | 0.260 |
Why?
|
| Benzhydryl Compounds | 2 | 2011 | 941 | 0.260 |
Why?
|
| Malingering | 1 | 2006 | 75 | 0.260 |
Why?
|
| Abbreviations as Topic | 1 | 2005 | 8 | 0.260 |
Why?
|
| Social Behavior | 2 | 2012 | 1131 | 0.260 |
Why?
|
| Vaccination | 3 | 2023 | 3361 | 0.260 |
Why?
|
| Indans | 1 | 2005 | 91 | 0.250 |
Why?
|
| Bradycardia | 1 | 2007 | 299 | 0.250 |
Why?
|
| HIV Seropositivity | 1 | 2010 | 955 | 0.240 |
Why?
|
| Self Psychology | 1 | 2004 | 8 | 0.240 |
Why?
|
| Prochlorperazine | 1 | 2004 | 16 | 0.240 |
Why?
|
| Aphonia | 1 | 2004 | 4 | 0.240 |
Why?
|
| Emetics | 1 | 2004 | 9 | 0.240 |
Why?
|
| Psychopharmacology | 1 | 2006 | 148 | 0.230 |
Why?
|
| Ipratropium | 1 | 2004 | 19 | 0.230 |
Why?
|
| Neuropsychological Tests | 14 | 2019 | 7021 | 0.230 |
Why?
|
| Administration, Sublingual | 1 | 2004 | 58 | 0.230 |
Why?
|
| Community Mental Health Services | 2 | 2021 | 392 | 0.230 |
Why?
|
| Curriculum | 2 | 2018 | 3718 | 0.230 |
Why?
|
| Depression | 6 | 2019 | 8044 | 0.230 |
Why?
|
| Salivary Glands | 1 | 2005 | 229 | 0.220 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 749 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2010 | 539 | 0.220 |
Why?
|
| Bupropion | 4 | 2007 | 304 | 0.220 |
Why?
|
| Pirenzepine | 1 | 2003 | 116 | 0.210 |
Why?
|
| Coma | 1 | 2007 | 487 | 0.210 |
Why?
|
| Lorazepam | 2 | 2018 | 154 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4573 | 0.210 |
Why?
|
| Bipolar Disorder | 5 | 2020 | 5078 | 0.210 |
Why?
|
| Electronic Health Records | 1 | 2020 | 4775 | 0.210 |
Why?
|
| Quality of Life | 4 | 2019 | 13308 | 0.210 |
Why?
|
| Adrenergic Antagonists | 1 | 2002 | 26 | 0.200 |
Why?
|
| Evidence-Based Medicine | 4 | 2013 | 3696 | 0.200 |
Why?
|
| Priapism | 1 | 2002 | 29 | 0.200 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 3 | 2008 | 275 | 0.200 |
Why?
|
| Treatment Outcome | 25 | 2021 | 65017 | 0.200 |
Why?
|
| Antipyretics | 1 | 2021 | 23 | 0.200 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 1313 | 0.200 |
Why?
|
| Communication | 1 | 2016 | 3849 | 0.200 |
Why?
|
| Endarterectomy, Carotid | 1 | 2007 | 564 | 0.190 |
Why?
|
| Attitude to Health | 5 | 2009 | 2029 | 0.190 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 1416 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2012 | 10827 | 0.190 |
Why?
|
| Frontal Lobe | 2 | 2006 | 1420 | 0.190 |
Why?
|
| Autonomic Dysreflexia | 1 | 2001 | 9 | 0.190 |
Why?
|
| Pilot Projects | 8 | 2022 | 8555 | 0.190 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 1903 | 0.180 |
Why?
|
| Dystonia | 1 | 2004 | 364 | 0.180 |
Why?
|
| Piperidines | 2 | 2007 | 1650 | 0.180 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 2363 | 0.180 |
Why?
|
| Personal Autonomy | 2 | 2012 | 302 | 0.170 |
Why?
|
| Education, Medical | 1 | 2011 | 1727 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 878 | 0.170 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2890 | 0.170 |
Why?
|
| Outpatients | 3 | 2023 | 1607 | 0.170 |
Why?
|
| Forensic Psychiatry | 2 | 2014 | 195 | 0.170 |
Why?
|
| Anemia, Pernicious | 1 | 2019 | 15 | 0.160 |
Why?
|
| Hippocampus | 5 | 2023 | 3738 | 0.160 |
Why?
|
| Nitroprusside | 1 | 2019 | 273 | 0.160 |
Why?
|
| Colonic Diseases | 1 | 2000 | 200 | 0.160 |
Why?
|
| Insulin | 7 | 2019 | 6597 | 0.160 |
Why?
|
| Nicotine | 6 | 2008 | 677 | 0.160 |
Why?
|
| Tuberculosis | 1 | 2012 | 2001 | 0.160 |
Why?
|
| Hypoglycemic Agents | 4 | 2013 | 3150 | 0.160 |
Why?
|
| Perphenazine | 1 | 2018 | 33 | 0.160 |
Why?
|
| Intestinal Perforation | 1 | 2000 | 250 | 0.160 |
Why?
|
| Placebos | 6 | 2009 | 1668 | 0.160 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2014 | 4555 | 0.160 |
Why?
|
| Affect | 3 | 2007 | 1480 | 0.160 |
Why?
|
| Peritonitis | 1 | 2000 | 369 | 0.150 |
Why?
|
| Hospitals, General | 1 | 2003 | 795 | 0.150 |
Why?
|
| Recurrence | 4 | 2021 | 8482 | 0.150 |
Why?
|
| Caregivers | 1 | 2010 | 2224 | 0.150 |
Why?
|
| Paresthesia | 1 | 2019 | 162 | 0.150 |
Why?
|
| Lipid Metabolism | 5 | 2014 | 1902 | 0.150 |
Why?
|
| Dopamine | 2 | 2008 | 1595 | 0.150 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 225 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2021 | 536 | 0.150 |
Why?
|
| Thiazolidinediones | 2 | 2012 | 465 | 0.150 |
Why?
|
| Acetaminophen | 1 | 2021 | 553 | 0.150 |
Why?
|
| Neutrophils | 1 | 2010 | 3767 | 0.140 |
Why?
|
| Vitamin B 12 | 2 | 2019 | 522 | 0.140 |
Why?
|
| Ambulatory Care | 5 | 2008 | 2781 | 0.140 |
Why?
|
| Nicotinic Agonists | 3 | 2008 | 265 | 0.140 |
Why?
|
| Gene Expression | 1 | 2010 | 7588 | 0.140 |
Why?
|
| Prolactin | 2 | 2010 | 621 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2010 | 3736 | 0.140 |
Why?
|
| Primary Health Care | 2 | 2019 | 4647 | 0.140 |
Why?
|
| Delusions | 1 | 2019 | 298 | 0.140 |
Why?
|
| Posture | 1 | 2001 | 953 | 0.140 |
Why?
|
| Stereotyping | 2 | 2011 | 239 | 0.140 |
Why?
|
| Teaching | 1 | 2004 | 1169 | 0.130 |
Why?
|
| Carcinoma, Ductal | 1 | 2016 | 97 | 0.130 |
Why?
|
| Liver | 1 | 2012 | 7509 | 0.130 |
Why?
|
| Leukocyte Count | 2 | 2010 | 1600 | 0.130 |
Why?
|
| Cyclobutanes | 2 | 2007 | 57 | 0.130 |
Why?
|
| Benzoates | 1 | 2017 | 212 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2018 | 956 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 2569 | 0.130 |
Why?
|
| Appetite Depressants | 2 | 2007 | 108 | 0.130 |
Why?
|
| Awareness | 3 | 2009 | 646 | 0.130 |
Why?
|
| Blood Glucose | 9 | 2011 | 6381 | 0.120 |
Why?
|
| Amantadine | 1 | 1995 | 57 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 558 | 0.120 |
Why?
|
| Weight Gain | 4 | 2013 | 2347 | 0.120 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2008 | 238 | 0.120 |
Why?
|
| Community Health Services | 1 | 2020 | 654 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2023 | 2773 | 0.120 |
Why?
|
| Head Injuries, Closed | 1 | 1996 | 133 | 0.120 |
Why?
|
| Cytokines | 1 | 2010 | 7343 | 0.120 |
Why?
|
| Models, Biological | 2 | 2010 | 9467 | 0.120 |
Why?
|
| Immunoassay | 1 | 2018 | 746 | 0.120 |
Why?
|
| Self Care | 1 | 2020 | 793 | 0.120 |
Why?
|
| Body Weight | 8 | 2019 | 4611 | 0.120 |
Why?
|
| Mass Screening | 2 | 2007 | 5423 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 435 | 0.120 |
Why?
|
| Administration, Intranasal | 4 | 2013 | 471 | 0.120 |
Why?
|
| Chronic Disease | 7 | 2013 | 9287 | 0.120 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1995 | 165 | 0.120 |
Why?
|
| Cellulitis | 1 | 2016 | 207 | 0.120 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 1399 | 0.120 |
Why?
|
| Suicide | 1 | 2005 | 1599 | 0.120 |
Why?
|
| Aged | 20 | 2022 | 169152 | 0.120 |
Why?
|
| Health Personnel | 2 | 2023 | 3310 | 0.110 |
Why?
|
| Boston | 2 | 2021 | 9280 | 0.110 |
Why?
|
| Clinical Competence | 3 | 2018 | 4783 | 0.110 |
Why?
|
| Homocysteine | 3 | 2007 | 640 | 0.110 |
Why?
|
| Halfway Houses | 1 | 2013 | 11 | 0.110 |
Why?
|
| Group Processes | 1 | 2015 | 226 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 7475 | 0.110 |
Why?
|
| Hallucinations | 1 | 1996 | 366 | 0.110 |
Why?
|
| Cross-Sectional Studies | 12 | 2019 | 25942 | 0.110 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2005 | 297 | 0.110 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2016 | 3701 | 0.110 |
Why?
|
| Cognition | 4 | 2013 | 6957 | 0.110 |
Why?
|
| Massachusetts | 4 | 2020 | 8803 | 0.100 |
Why?
|
| Pravastatin | 1 | 2014 | 393 | 0.100 |
Why?
|
| Young Adult | 9 | 2022 | 58741 | 0.100 |
Why?
|
| Comorbidity | 8 | 2015 | 10551 | 0.100 |
Why?
|
| Insulin Resistance | 7 | 2010 | 3959 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 2628 | 0.100 |
Why?
|
| Anthropometry | 4 | 2011 | 1348 | 0.100 |
Why?
|
| Waist Circumference | 3 | 2013 | 926 | 0.100 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 1178 | 0.100 |
Why?
|
| Electroencephalography | 3 | 2009 | 6189 | 0.100 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2012 | 303 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 2016 | 407 | 0.100 |
Why?
|
| Follow-Up Studies | 11 | 2023 | 39261 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2017 | 1195 | 0.090 |
Why?
|
| Substance-Related Disorders | 2 | 2013 | 4371 | 0.090 |
Why?
|
| Bioethics | 1 | 2012 | 117 | 0.090 |
Why?
|
| Verbal Learning | 2 | 2011 | 462 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2192 | 0.090 |
Why?
|
| Leg | 1 | 2016 | 1090 | 0.090 |
Why?
|
| Drug Administration Schedule | 5 | 2004 | 4899 | 0.090 |
Why?
|
| Indenes | 1 | 2011 | 58 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5397 | 0.090 |
Why?
|
| Glucose | 6 | 2019 | 4351 | 0.090 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2010 | 1079 | 0.090 |
Why?
|
| Consensus | 1 | 2020 | 3113 | 0.090 |
Why?
|
| Time Factors | 8 | 2021 | 40165 | 0.090 |
Why?
|
| Analysis of Variance | 8 | 2013 | 6238 | 0.090 |
Why?
|
| Africa, Western | 1 | 2010 | 159 | 0.090 |
Why?
|
| Anorexia | 1 | 2010 | 154 | 0.090 |
Why?
|
| Smoking | 7 | 2019 | 9073 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 2315 | 0.090 |
Why?
|
| Dopamine Antagonists | 1 | 2010 | 288 | 0.080 |
Why?
|
| Glucose Tolerance Test | 5 | 2012 | 1175 | 0.080 |
Why?
|
| Anxiety Disorders | 1 | 2001 | 2714 | 0.080 |
Why?
|
| Body Mass Index | 10 | 2019 | 12914 | 0.080 |
Why?
|
| Confusion | 1 | 2011 | 279 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2012 | 2511 | 0.080 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2010 | 189 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 496 | 0.080 |
Why?
|
| Attention | 5 | 2011 | 2387 | 0.080 |
Why?
|
| Philosophy | 1 | 2009 | 68 | 0.080 |
Why?
|
| Disease Management | 2 | 2016 | 2514 | 0.080 |
Why?
|
| Facility Regulation and Control | 1 | 2008 | 24 | 0.080 |
Why?
|
| Obesity | 7 | 2011 | 12922 | 0.080 |
Why?
|
| Mental Health | 1 | 2023 | 3213 | 0.080 |
Why?
|
| Granulocytes | 1 | 2010 | 551 | 0.080 |
Why?
|
| Pyridines | 1 | 2000 | 2879 | 0.080 |
Why?
|
| Eating | 2 | 2012 | 1539 | 0.080 |
Why?
|
| Galantamine | 1 | 2008 | 33 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2010 | 2932 | 0.070 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 5889 | 0.070 |
Why?
|
| Dopamine Agonists | 1 | 2010 | 352 | 0.070 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 464 | 0.070 |
Why?
|
| Health Policy | 1 | 2020 | 2677 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 214 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2012 | 1180 | 0.070 |
Why?
|
| Basal Ganglia Diseases | 2 | 2004 | 144 | 0.070 |
Why?
|
| C-Reactive Protein | 4 | 2021 | 3839 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2014 | 987 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2014 | 1754 | 0.070 |
Why?
|
| Dioxoles | 1 | 2007 | 95 | 0.070 |
Why?
|
| Psychopathology | 1 | 2010 | 429 | 0.070 |
Why?
|
| Personality Assessment | 1 | 2009 | 650 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2023 | 36290 | 0.070 |
Why?
|
| Amiodarone | 1 | 2008 | 218 | 0.070 |
Why?
|
| Needs Assessment | 1 | 2012 | 1139 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 4291 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2008 | 251 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 8056 | 0.070 |
Why?
|
| Memory | 3 | 2011 | 2179 | 0.070 |
Why?
|
| Air Pollution | 1 | 2020 | 2317 | 0.070 |
Why?
|
| Professional-Family Relations | 1 | 2010 | 495 | 0.070 |
Why?
|
| Informed Consent | 1 | 2012 | 1005 | 0.070 |
Why?
|
| Dibenzothiazepines | 1 | 2006 | 102 | 0.070 |
Why?
|
| Consciousness | 1 | 2011 | 602 | 0.060 |
Why?
|
| Sulfones | 1 | 2008 | 447 | 0.060 |
Why?
|
| Radiography | 2 | 2019 | 6965 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2010 | 882 | 0.060 |
Why?
|
| Atrophy | 2 | 2021 | 1627 | 0.060 |
Why?
|
| Ownership | 1 | 2008 | 339 | 0.060 |
Why?
|
| China | 2 | 2023 | 2339 | 0.060 |
Why?
|
| Self Concept | 1 | 2011 | 1039 | 0.060 |
Why?
|
| Social Environment | 1 | 2010 | 1022 | 0.060 |
Why?
|
| Severity of Illness Index | 5 | 2010 | 15840 | 0.060 |
Why?
|
| Anxiety | 2 | 2010 | 4538 | 0.060 |
Why?
|
| Capsules | 1 | 2005 | 192 | 0.060 |
Why?
|
| Sulpiride | 1 | 2004 | 15 | 0.060 |
Why?
|
| Dyskinesias | 1 | 2005 | 79 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3202 | 0.060 |
Why?
|
| Culture | 1 | 2009 | 622 | 0.060 |
Why?
|
| Age Factors | 1 | 2021 | 18416 | 0.060 |
Why?
|
| Adolescent | 8 | 2021 | 87810 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 936 | 0.060 |
Why?
|
| Risk Factors | 8 | 2021 | 74359 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 961 | 0.060 |
Why?
|
| Brain | 3 | 2009 | 26951 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 867 | 0.060 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2021 | 109 | 0.060 |
Why?
|
| Prevalence | 4 | 2009 | 15687 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1784 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2002 | 4744 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2852 | 0.060 |
Why?
|
| Hemoglobins | 2 | 2007 | 1521 | 0.060 |
Why?
|
| Work Schedule Tolerance | 1 | 2008 | 551 | 0.060 |
Why?
|
| Diphenhydramine | 1 | 2004 | 63 | 0.060 |
Why?
|
| Cycloserine | 1 | 2004 | 118 | 0.060 |
Why?
|
| Life Change Events | 2 | 2008 | 952 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2011 | 2659 | 0.060 |
Why?
|
| Poisoning | 1 | 2005 | 252 | 0.060 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 357 | 0.060 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2007 | 257 | 0.060 |
Why?
|
| Morbidity | 2 | 2009 | 1765 | 0.060 |
Why?
|
| Hyperlipidemias | 2 | 2005 | 782 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 981 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2010 | 1197 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2024 | 80372 | 0.050 |
Why?
|
| Gyrus Cinguli | 1 | 2009 | 1114 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 3986 | 0.050 |
Why?
|
| United States | 7 | 2017 | 72461 | 0.050 |
Why?
|
| Viral Load | 1 | 2012 | 3322 | 0.050 |
Why?
|
| Wakefulness | 1 | 2009 | 1255 | 0.050 |
Why?
|
| Antiemetics | 1 | 2004 | 187 | 0.050 |
Why?
|
| Workload | 1 | 2008 | 847 | 0.050 |
Why?
|
| Motor Activity | 1 | 2012 | 2687 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2010 | 1992 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 989 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 2197 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2003 | 4035 | 0.050 |
Why?
|
| Thiazoles | 1 | 2009 | 1511 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 2176 | 0.050 |
Why?
|
| Adiposity | 1 | 2011 | 1858 | 0.050 |
Why?
|
| Neurochemistry | 1 | 2001 | 29 | 0.050 |
Why?
|
| Nucleus Accumbens | 1 | 2004 | 365 | 0.050 |
Why?
|
| Aerosols | 1 | 2004 | 632 | 0.050 |
Why?
|
| Prognosis | 3 | 2009 | 29658 | 0.050 |
Why?
|
| Folic Acid | 2 | 2006 | 1309 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2004 | 1018 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 2061 | 0.050 |
Why?
|
| Hyperhidrosis | 1 | 2001 | 34 | 0.050 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 3388 | 0.040 |
Why?
|
| Headache | 2 | 2015 | 1249 | 0.040 |
Why?
|
| Triglycerides | 3 | 2019 | 2476 | 0.040 |
Why?
|
| Mental Recall | 1 | 2006 | 1206 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3486 | 0.040 |
Why?
|
| Age of Onset | 1 | 2007 | 3301 | 0.040 |
Why?
|
| Body Composition | 3 | 2019 | 2419 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2005 | 908 | 0.040 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 1864 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2013 | 2809 | 0.040 |
Why?
|
| Quality Improvement | 2 | 2012 | 3836 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 21025 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 5877 | 0.040 |
Why?
|
| Inflammation | 3 | 2021 | 10756 | 0.040 |
Why?
|
| Weight Loss | 1 | 2010 | 2686 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2021 | 441 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 422 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 5496 | 0.040 |
Why?
|
| Motivation | 1 | 2009 | 1993 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9276 | 0.040 |
Why?
|
| Psychomotor Performance | 4 | 2008 | 1878 | 0.040 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 2212 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 58995 | 0.040 |
Why?
|
| Energy Intake | 1 | 2006 | 2129 | 0.040 |
Why?
|
| Students, Medical | 1 | 2011 | 1927 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2021 | 364 | 0.040 |
Why?
|
| Employment | 1 | 2004 | 1112 | 0.040 |
Why?
|
| Lung | 1 | 2016 | 9994 | 0.040 |
Why?
|
| Glycemic Index | 1 | 2020 | 396 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 13262 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 2001 | 959 | 0.040 |
Why?
|
| Troponin | 1 | 2021 | 516 | 0.040 |
Why?
|
| Cities | 1 | 2020 | 538 | 0.040 |
Why?
|
| Emotions | 1 | 2009 | 2734 | 0.040 |
Why?
|
| Waist-Hip Ratio | 2 | 2010 | 516 | 0.040 |
Why?
|
| Mental Health Services | 2 | 2013 | 1717 | 0.040 |
Why?
|
| Terminology as Topic | 1 | 2004 | 1535 | 0.030 |
Why?
|
| Students | 1 | 2006 | 1730 | 0.030 |
Why?
|
| Absorptiometry, Photon | 2 | 2013 | 1736 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 3143 | 0.030 |
Why?
|
| Sex Factors | 3 | 2013 | 10547 | 0.030 |
Why?
|
| Community Mental Health Centers | 2 | 2006 | 93 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 12293 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2019 | 916 | 0.030 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 713 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2019 | 421 | 0.030 |
Why?
|
| Pain | 1 | 2010 | 5066 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2006 | 2869 | 0.030 |
Why?
|
| Drug Costs | 1 | 2003 | 1185 | 0.030 |
Why?
|
| Risk | 2 | 2007 | 9631 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2234 | 0.030 |
Why?
|
| Cardiovascular Diseases | 3 | 2012 | 15757 | 0.030 |
Why?
|
| Health Status | 4 | 2009 | 4081 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1995 | 553 | 0.030 |
Why?
|
| Cholesterol | 3 | 2009 | 2924 | 0.030 |
Why?
|
| Sample Size | 2 | 2007 | 840 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2006 | 3185 | 0.030 |
Why?
|
| Hand | 1 | 2019 | 903 | 0.030 |
Why?
|
| Principle-Based Ethics | 1 | 2012 | 11 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 8552 | 0.030 |
Why?
|
| Paternalism | 1 | 2012 | 47 | 0.030 |
Why?
|
| Head | 1 | 2019 | 922 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2004 | 3040 | 0.030 |
Why?
|
| Nutrition Assessment | 2 | 2006 | 727 | 0.030 |
Why?
|
| Reference Standards | 1 | 1996 | 1004 | 0.030 |
Why?
|
| Laboratories | 1 | 1996 | 462 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2009 | 2061 | 0.020 |
Why?
|
| Fear | 1 | 2021 | 1462 | 0.020 |
Why?
|
| Patient Rights | 1 | 2012 | 125 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2001 | 1640 | 0.020 |
Why?
|
| Medical Audit | 1 | 2013 | 452 | 0.020 |
Why?
|
| Evoked Potentials | 1 | 1997 | 1036 | 0.020 |
Why?
|
| Logistic Models | 3 | 2012 | 13314 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2001 | 1223 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2012 | 3765 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 5508 | 0.020 |
Why?
|
| Fasting | 2 | 2007 | 1603 | 0.020 |
Why?
|
| Incidence | 3 | 2007 | 21392 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 511 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3106 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 2010 | 201 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2012 | 641 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2012 | 484 | 0.020 |
Why?
|
| Carbon Monoxide | 2 | 2007 | 540 | 0.020 |
Why?
|
| Polymethacrylic Acids | 1 | 2008 | 32 | 0.020 |
Why?
|
| Chewing Gum | 1 | 2008 | 40 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 15789 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 2010 | 388 | 0.020 |
Why?
|
| Genotype | 3 | 2008 | 12960 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2008 | 47 | 0.020 |
Why?
|
| Diet Records | 1 | 2010 | 427 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2004 | 41335 | 0.020 |
Why?
|
| Health Services | 1 | 2013 | 753 | 0.020 |
Why?
|
| Polyvinyls | 1 | 2008 | 154 | 0.020 |
Why?
|
| Pteroylpolyglutamic Acids | 1 | 2007 | 9 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 13630 | 0.020 |
Why?
|
| Food Preferences | 1 | 2010 | 399 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2006 | 174 | 0.020 |
Why?
|
| Methionine | 1 | 2008 | 569 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 667 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2007 | 335 | 0.020 |
Why?
|
| Reference Values | 2 | 2006 | 4925 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 20509 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 17790 | 0.020 |
Why?
|
| Purines | 1 | 2008 | 605 | 0.020 |
Why?
|
| Patient Care Management | 1 | 2008 | 303 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2021 | 54303 | 0.020 |
Why?
|
| Periodicity | 1 | 2006 | 348 | 0.010 |
Why?
|
| Cause of Death | 2 | 2005 | 3725 | 0.010 |
Why?
|
| Seizures | 1 | 1997 | 2917 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2004 | 81 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 1737 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2016 | 3726 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2011 | 8525 | 0.010 |
Why?
|
| Hospitalization | 3 | 2016 | 10790 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 1171 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 2754 | 0.010 |
Why?
|
| Caffeine | 1 | 2006 | 702 | 0.010 |
Why?
|
| Hypertension | 2 | 2015 | 8594 | 0.010 |
Why?
|
| Patient Transfer | 1 | 2008 | 779 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2010 | 22053 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 622 | 0.010 |
Why?
|
| Lipids | 1 | 2011 | 3336 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2009 | 1380 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3615 | 0.010 |
Why?
|
| Prediabetic State | 1 | 2006 | 550 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2005 | 868 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2010 | 2283 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2006 | 2362 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 2420 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4107 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6360 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 10344 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5251 | 0.010 |
Why?
|
| Urban Population | 1 | 2006 | 2022 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24123 | 0.010 |
Why?
|
| Overweight | 1 | 2009 | 2421 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2006 | 1607 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2010 | 9716 | 0.010 |
Why?
|
| Nerve Net | 1 | 2009 | 2261 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2005 | 1207 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 2629 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 3758 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 12159 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 4193 | 0.010 |
Why?
|
| Homeostasis | 1 | 2006 | 3306 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2008 | 4373 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 15289 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 16546 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10182 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 3865 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2006 | 6568 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2005 | 5990 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 8950 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 14495 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 167963 | 0.000 |
Why?
|
| Aging | 1 | 2006 | 8651 | 0.000 |
Why?
|
| Diet | 1 | 2004 | 8010 | 0.000 |
Why?
|